Our Q2 2024 earnings results are now available. Learn more about our commitment to making an impact for patients around the globe: https://lnkd.in/deXeqQSY
About us
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter) and Facebook.
- Website
-
http://www.beigene.com
External link for BeiGene
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
- Founded
- 2010
- Specialties
- targeted therapy, immuno-oncology, hematology, oncology, and cancer
Locations
Employees at BeiGene
-
Andrew Harmon
Clinical recruiter at BeiGene
-
Roger Ralph TSCHOPP M.D., M.Sc.
Senior Medical Director, Global Medical Affairs at BeiGene
-
Scott Carter
VP, Associate General Counsel, Business Development at BeiGene
-
Alex Emanuel
Healthcare marketer, commercial operations and analytics professional
Updates
-
We’re honored to be receiving The Lymphoma Research Foundation’s 2024 Corporate Leadership Award! This award underscores our commitment to improving outcomes for patients with #lymphoma by advancing groundbreaking science and supporting the Foundation's research initiatives and education programs. We thank the Foundation for their ongoing partnership with BeiGene and for their dedication to supporting patients. Hear more from Dany Habr, M.D., our Head of Medical Affairs, North America & International Markets. Learn more: https://bit.ly/4dxI8Wp.
-
In alignment with our commitment to advancing global health equity, we’re partnering with The Max Foundation to bring our innovative medicine to patients with chronic lymphocytic leukemia (#CLL) in low- and middle-income countries. Last week, we were honored to welcome Pat Garcia-Gonzalez, CEO of The Max Foundation, Cathy Scheepers, Region Head for Africa at The Max Foundation, and Dr. Fisihatsion Tadesse, an Ethiopian hematologist. They joined Melika Davis, our Head of Global Clinical Operations, in a profound discussion on the challenges of CLL treatment in Ethiopia. Our collaboration with The Max Foundation stands as a crucial step in addressing the pressing needs of patients and clinics across the country. Watch the video to learn more. #HealthEquity #PatientsFirst
-
Javad Shahidi, SVP and Head of our Biotech Unit, recently joined other industry R&D leaders to discuss the evolving landscape of #oncology drug development, highlighting a key focus of ours – access to innovative medicines for more patients around the world.
It was a pleasure to join the roundtable conversation hosted by Scrip during #ASCO24. The lively discussion touched on many aspects of #oncology drug development, and I was excited to share BeiGene’s perspective on prioritizing global access to innovative medicines. Read the Citeline and ICON plc executive summary of the event here: https://bit.ly/4fqO2dI
-
BeiGene reposted this
Last week’s grand opening of our new flagship U.S. manufacturing and clinical R&D site in Hopewell, N.J., marks a significant leap forward for BeiGene as we advance our position as a leading innovator in #oncology and expand our global footprint. I am profoundly grateful to the BeiGene team for their outstanding dedication and remarkable efficiency in bringing this site to fruition in such a short timeframe.
A Big Moment in BeiGene’s 14-Year History
John Oyler on LinkedIn
-
We believe effective #cancer care goes beyond physical treatments. We recognize the profound mental challenges that come with a diagnosis and are committed to making mental health and emotional wellness an integral part of quality cancer care. That’s why we’ve launched the "Talk About It: Cancer and Mental Health" program to offer more resources and support for patients and their loved ones. Learn more at https://bit.ly/3VS5H6r. #TalkAboutIt #MentalHealth #CancerCare
-
Watch the highlights from the grand opening of our flagship U.S. facility in Hopewell, N.J. last week. This state-of-the-art manufacturing and clinical R&D site will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance impactful medicines faster for #cancer patients worldwide. https://bit.ly/4c5EHVC
U.S. Manufacturing and Clinical R&D Facility Grand Opening
https://www.youtube.com/
-
As part of our commitment to supporting our communities, we introduced a global volunteer time-off policy last year that allows BeiGene colleagues to take up to eight hours of paid time off each year to volunteer. Recently, our colleagues in Chicago used this policy in volunteering with Nourishing Hope, sorting and packing about 200 boxes of food, many weighing more than 50 lbs., to help local families in need. Learn more about our culture of volunteerism in our Responsible Business & Sustainability Report: https://bit.ly/3QTIRs3
-
Our flagship U.S. biologics manufacturing and clinical R&D facility, opened this week in Hopewell, N.J., represents a huge step forward in our continuing growth as a leading #oncology company and the expansion of our global footprint. We’re committed to making a significant investment in New Jersey to ensure we’re a responsible and positive force in the community. The $800 million investment we’ve made in the site will create more than 100 high-tech skilled jobs locally by the end of 2025. Learn more in this Fierce Pharma article: https://bit.ly/3zZC6iU
BeiGene debuts $800M biologics plant set to create 'hundreds' of jobs in New Jersey
fiercepharma.com
-
We believe in advancing impactful #oncology medicines for patients around the world. Thanks to one of the largest and most prolific oncology R&D teams in the industry, our broad and growing pipeline has the potential to address 80 percent of #cancers by incidence. Learn more about our pipeline at https://bit.ly/3RGlwdO.